Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Patient and public understanding and knowledge of antimicrobial resistance and stewardship in a UK hospital: should public campaigns change focus?

Micallef C, Kildonaviciute K, Castro-Sánchez E, Scibor-Stepien A, Santos R, Aliyu SH, Cooke FJ, Pacey S, Holmes AH, Enoch DA.

J Antimicrob Chemother. 2017 Jan;72(1):311-314.

PMID:
27655854
2.

Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.

Al-Lamki RS, Wang J, Yang J, Burrows N, Maxwell PH, Eisen T, Warren AY, Vanharanta S, Pacey S, Vandenabeele P, Pober JS, Bradley JR.

Oncotarget. 2016 Apr 26;7(17):24111-24. doi: 10.18632/oncotarget.8125.

3.

Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial.

Forrester DL, Knox AJ, Smyth AR, Barr HL, Simms R, Pacey SJ, Pavord ID, Honeybourne D, Dewar J, Clayton A, Fogarty AW.

Pediatr Pulmonol. 2016 Mar;51(3):253-7. doi: 10.1002/ppul.23370.

PMID:
26709241
4.

Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.

Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PA, Lindley RI, Wardlaw JM; IST-3 Collaborative Group..

Neurology. 2016 Jan 12;86(2):118-25. doi: 10.1212/WNL.0000000000002236.

5.

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

Tan CS, Gilligan D, Pacey S.

Lancet Oncol. 2015 Sep;16(9):e447-59. doi: 10.1016/S1470-2045(15)00246-6. Review.

PMID:
26370354
6.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, Temple G, Bell S, Stefanic M, Stopfer P, Tang A, Koh DM, Collins DJ, d'Arcy J, Padhani AR, Leach MO, Judson IR, Rustin GJ.

Oncologist. 2015 Apr;20(4):368-9. doi: 10.1634/theoncologist.2014-0250.

7.

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC.

Clin Cancer Res. 2014 Aug 15;20(16):4251-61. doi: 10.1158/1078-0432.CCR-14-0341.

8.

A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.

Powles T, Foreshew SJ, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L, Pungaliya A, Foreshaw A, Davies R, Greenwood M, Wilson P, Pacey S, Galazi M, Jones R, Chowdhury S.

Eur J Cancer. 2014 Aug;50(12):2057-64. doi: 10.1016/j.ejca.2014.04.021.

PMID:
24908540
9.

A 46 year old man with carcinoma of unknown primary site.

Liniker E, Al-Jilaihawi S, Propper D, Slater S, Pacey S.

BMJ. 2012 Aug 2;345:e5144. doi: 10.1136/bmj.e5144. No abstract available.

PMID:
22859798
10.

Another patient with low back pain.

O'Leary B, Eminowicz G, Powell ME, Pacey S.

BMJ. 2012 Jun 14;344:e3510. doi: 10.1136/bmj.e3510. No abstract available.

PMID:
22700783
11.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group., Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

12.

Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.

Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, Whiteley W, Perry D, Soosay V, Buchanan D, Venables G, Czlonkowska A, Kobayashi A, Berge E, Slot KB, Murray V, Peeters A, Hankey GJ, Matz K, Brainin M, Ricci S, Cantisani TA, Gubitz G, Phillips SJ, Antonio A, Correia M, Lyrer P, Kane I, Lundstrom E; IST-3 collaborative group..

Trials. 2011 Nov 30;12:252. doi: 10.1186/1745-6215-12-252.

13.

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.

Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I.

Clin Cancer Res. 2011 Mar 15;17(6):1561-70. doi: 10.1158/1078-0432.CCR-10-1927.

14.

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T.

Invest New Drugs. 2012 Feb;30(1):341-9. doi: 10.1007/s10637-010-9493-4.

PMID:
20683637
15.

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.

Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba MN, Egorin MJ, Ivy P, Pacey S, Lorusso PM.

Clin Cancer Res. 2010 Jul 15;16(14):3795-804. doi: 10.1158/1078-0432.CCR-10-0503.

16.

Impact of adopting low sodium diet on biomarkers of inflammation and coagulation: a randomised controlled trial.

Forrester DL, Britton J, Lewis SA, Pogson Z, Antoniak M, Pacey SJ, Purcell G, Fogarty AW.

J Nephrol. 2010 Jan-Feb;23(1):49-54.

PMID:
20091486
17.

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.

Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR.

Invest New Drugs. 2011 Jun;29(3):481-8. doi: 10.1007/s10637-009-9367-9.

PMID:
20016927
18.

Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.

Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, Workman P.

Cancer Res. 2009 Mar 1;69(5):1966-75. doi: 10.1158/0008-5472.CAN-08-3131. Erratum in: Cancer Res. 2009 Apr 15;69(8):3721.

19.

Does a low sodium diet modify heart rate variability? A randomised placebo-controlled double-blind trial.

Pogson ZE, McKeever TM, Lewis SA, Pacey SJ, Antoniak MD, Britton JR, Fogarty AW.

Int J Cardiol. 2009 Jul 10;135(3):390-3. doi: 10.1016/j.ijcard.2008.11.004.

PMID:
19062112
20.

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.

de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A.

Clin Cancer Res. 2008 Oct 15;14(20):6663-73. doi: 10.1158/1078-0432.CCR-08-0376.

Items per page

Supplemental Content

Loading ...
Support Center